SALT LAKE CITY, UT--(Marketwire - November 01, 2007) - Myriad Genetics, Inc. (NASDAQ: MYGN) today reported financial results for the first quarter of fiscal 2008. For the three-month period ended September 30, 2007, molecular diagnostic revenue increased to $46.1 million from $30.9 million in the same three months in 2006, an increase of 49%. The majority of this growth resulted from increased customer demand and accelerated market penetration, and included an encouraging level of initial sales of the Company's newest product, TheraGuide 5-FU™.
